Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies, NCI Collaborate on Immunosequencing Biomarker Discovery

NEW YORK (GenomeWeb) – Adaptive Biotechnologies and the Cancer Therapy Evaluation Program of the National Cancer Institute will work together to try to identify immune repertoire dynamics that drive cancer immunotherapy responses.

Under the collaboration, the researchers will use Adaptive's ImmunoSeq platform to sequence the T cell and B cell repertoires of patients in select NCI clinical trials. The researchers hope that by expanding the use of immunosequencing, they may better understand and predict response to novel immuno-modulatory agents.

The goal is to "help expedite the development of new immune molecular biomarkers that inform the next wave of novel therapies and rational combinations," Chad Robins, Adaptive founder and CEO, said in a statement.